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Tibolone, a synthetic steroid acting in a tissue-specific man-
ner and used in hormone replacement therapy, is converted
into three active metabolites: a 4 isomer (exerting progesta-
genic and androgenic effects) and two hydroxy metabolites,
3-hydroxytibolone (3-OH-tibolone) and 3-OH-tibolone (ex-
erting estrogenic effects). In the present study an endometrial
carcinoma cell line (Ishikawa PRAB-36) was used to investi-
gate the progestagenic properties of tibolone and its meta-
bolites. This cell line contains progesterone receptors A and B,
but lacks estrogen and androgen receptors.
When tibolone was added to the cells, complete conversion
into the progestagenic/androgenic 4 isomer was observed
within 6 d. Furthermore, when cells were cultured with tibo-
lone or when the 4 isomer or the established progestagen
medroxyprogesterone acetate was added to the medium,
marked inhibition of growth was observed. Interestingly, 3-
OH-tibolone also induces some inhibition of growth. These
growth inhibitions were not observed in progesterone receptor-
negative parental Ishikawa cells, and progestagen-induced
growth inhibition of PRAB-36 cells could readily be reversed
using the antiprogestagen Org-31489. Upon measuring the ex-
pression of two progesterone-regulated genes (fibronectin
and IGF-binding protein-3), tibolone, the 4 isomer and me-
droxyprogesterone acetate showed similar gene expression
regulation.
These results indicate that tibolone, the 4 metabolite, and
to some extent 3-OH-tibolone exert progestagenic effects.
Tibolone and most likely 3-OH-tibolone are converted into
the 4 metabolite. (J Clin Endocrinol Metab 88: 2327–2334,
2003)
WITH MENOPAUSE, THE ovaries stop ovulating, andcirculating levels of progesterone and estrogen de-
crease. Because of reduced levels of estrogens, women often
experience adverse effects (hot flushes, vaginal dryness, in-
creased bone loss, etc.). To relieve climacteric symptoms and
prevent osteoporosis, hormone replacement therapy may be
prescribed. At present, hormone replacement therapy usu-
ally contains separate estrogenic and progestagenic compo-
nents. The estrogenic component substitutes for the de-
creased circulating estrogens; the progestagenic component
reduces the adverse effects of estrogens on the endome-
trium (1).
Tibolone is a synthetic steroid that is commonly used for
the treatment of climacteric complaints and prevention of
osteoporosis (2). The compound itself does not bind with
high affinity to any of the known steroid receptors (3);
however, depending on the activity of different enzymes
during passage through the intestine and liver, tibolone
will be converted by 3-hydroxysteroid dehydrogenase
(3HSD) into its 4 isomer (4-tibolone) or its 3-reduced
derivative [3-hydroxytibolone (3-OH-tibolone)] and/or
by 3HSD into its 3-reduced derivative (3-OH-tibolone)
(4). In contrast to tibolone itself, these metabolic products
show higher affinity binding to several steroid receptors;
4-tibolone binds to progesterone and androgen receptors,
and 3-OH-tibolone and 3-OH-tibolone bind to estrogen
receptors (3).
Upon measurement of the metabolites of tibolone in
several animal tissues (5), it was observed that estrogenic
metabolites were formed (3-OH-tibolone and 3-OH-
tibolone). These metabolites, however, are quickly sul-
fated by sulfotransferases in the liver and intestine and
will only become active as estrogens upon removal of the
sulfate group by tissue-specific sulfatases (5). In breast
cancer cell lines, sulfatase activity is inhibited by tibolone,
and as a result of this, sulfated 3-OH-tibolone, sulfated
3-OH-tibolone, and sulfated endogenous estrogens will
no longer act as biologically active estrogens (6 –9). For the
human endometrial cancer cell line HEC-1A, De Gooyer et
al. (8) could show that sulfatase activity was also inhibited
by tibolone. Furthermore, Falany et al. (10) found that
sulfotransferases in the human endometrium are probably
up-regulated by progestagens. Together with the finding
that the progestagenic metabolite of tibolone (4-tibolone)
can locally be formed in the endometrium (3) and with
observations from clinical trails (11–15), these data seem to
indicate that the estrogenic activities of tibolone metabo-
lites on the endometrium are balanced by progestagenic
and other activities of tibolone and its metabolites on the
endometrium.
To study the progestagenic effects of tibolone treatment on
the endometrium in more detail, a progesterone-sensitive,
estrogen- and androgen receptor-negative, well differenti-
Abbreviations: DCC-FBS, Dextran-charcoal-treated fetal bovine se-
rum; FBS, fetal bovine serum; hPRA, human progesterone receptor-A;
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ated, human endometrial cancer cell line was used in the
current investigations. It was shown that by conversion of
tibolone into 4-tibolone significant progesterone receptor-
mediated growth inhibition and gene regulation could be
accomplished in these cells. These results indicate that the
4 isomer of tibolone exerts clear progestagenic effects on
progesterone-sensitive endometrial cancer cells.
Materials and Methods
Cell culture
Ishikawa cells are derived from a well differentiated endometrial
adenocarcinoma and were a gift from Dr. Masato Nishida (Tsukuba,
Japan) (16). The cells were negative for mycoplasma contamination,
determined using the Mycoplasma-Plus-PCR-Primer-Set (Stratagene, La
Jolla, CA). The cells were maintained in DMEM/Ham’s F-12 (Invitrogen,
Paisley, Scotland) and 5% fetal bovine serum (FBS; Perbio Science, Hels-
ingborg, Sweden) supplemented with penicillin/streptomycin in a 37 C
incubator at 5% CO2. The cells were transfected with human proges-
terone receptor-A (hPRA) and hPRB (17) and were maintained under
similar culture conditions, with continuous selection pressure using
neomycin (500 g/ml; G418, Invitrogen, Breda, The Netherlands) and
hygromycin (250 g/ml; Invitrogen).1
Compounds
Tibolone [(7,17)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-
yn-3-one], 3-OH-tibolone [(3,7,17)-7-methyl-19-norpregn-5(10)-en-
20-yn-3,17-diol], 3-OH-tibolone [(3,7,17)-7-methyl-19-norpregn-
5(10)-en-20-yn-3,17-diol], and 4-tibolone [(7,17)-17-hydroxy-7-
methyl-19-norpregn-4-en-20-yn-3-one] were provided as crystalline
powder containing less than 0.6% impurities by N.V. Organon (Oss, The
Netherlands). Tritiated compounds were also provided by N.V. Or-
ganon; the radiochemical purity of these tritiated compounds was above
97%, and specific activity ranged between 38–53 Ci/mmol. Medroxy-
progesterone acetate (MPA) was obtained from Sigma-Aldrich Corp. (St.
Louis, MO).
Growth studies
For all growth studies (Figs. 2–5) cells were passaged to 24-well plates
(Nalge Nunc International, Rochester, NY) in DMEM/Ham’s F-12 con-
taining 5% dextran-charcoal-treated FBS (DCC-FBS) for the indicated
times in the presence or absence of the indicated concentrations of
hormones. Cell density at the start of the experiments was 5000 cells/
cm2. After 10 d of culture, control cells were at approximately 75%
confluence. Hormones were added at the concentrations indicated in the
figure legends. At the end of each experiment medium was removed,
cells were washed twice using PBS, and the culture well plate was stored
at –20 C. After lysis in 1 n NaOH, OD260 nm measurements were per-
formed to measure cell growth (17). Within one experiment, cells were
cultured in quadruplicate.
HPLC analysis
PRAB-36 cells were cultured in DMEM/Ham’s F-12 and 5% DCC-
FBS for 3 or 6 d in the presence of 50 nm [3H]tibolone, [3H]3-OH-
tibolone, [3H]3-OH-tibolone, or [3H]4-tibolone. At 3 and 6 d of
culture, 200-l aliquots of medium were collected and immediately
acidified by adding 10 l 1 m HCl. After centrifugation, 100 l of this
sample were injected on the HPLC column. HPLC analysis was per-
formed using a Spherisorb ODS2 (Waters Corp., Milford, MA) col-
umn (4.6 250 mm) and a gradient of water (solvent A) and methanol
(solvent B). Elution was performed with a linear gradient of 60 – 80%
solvent B (vol/vol) for 40 min at 25 C. The flow rate was 1 ml/min.
HPLC analysis was performed with a type HP1100 (Hewlett-Packard
Co., Waldborn, Germany) and an injection volume of 40 l. Radio-
activity was determined on-line using a type A515 flow-through
Flo-One  radioactivity detector (Canberra Packard, Meridan, CA).
Western immunoblotting
The cells were cultured in DMEM/Ham’s F-12 and 5% DCC-FBS to
75% confluence. The cells were washed twice with PBS, lysed in RIPA
buffer [40 mm Tris-HCl (pH 7.4), 5 mm EDTA (pH 8.0), 10% glycerol,
10 mm sodium phosphate, 10 mm sodium molybdate, 50 mm sodium
fluoride, 0.5 mm sodium orthovanadate, 10 mm dithiothreitol, 1%
Triton, 0.08% sodium dodecyl sulfate, 0.5% deoxycholate, and pro-
tease inhibitors: 6 mm phenylmethylsulfonylfluoride, 5 mm bacitra-
cin, and 5 mm leupeptin] and centrifuged for 10 min at 350,000  g
1 Smid-Koopman, E., E. C. M. Ku¨hne, E. E. Hanekamp, S. C. J. P.
Gielen, P. E. De Ruiter, J. A. Grootegoed, T. J. M. Helmerhorst, C. W.
Burger, A. O. Brinkmann, F. J. Huikeshoven, and L. J. Blok, submitted
for publication.
FIG. 1. Progesterone receptor expression. The expression of proges-
terone receptors was measured by Western blot using a human pro-
gesterone receptor-specific polyclonal antibody. The human breast
cancer cell line T47D was used as a positive control. The arrows
indicate the positions of PRA and the three phosphorylated forms of
PRB in the gel. On the left side of the figure, the molecular mass is
indicated.
TABLE 1. Measurement of different metabolites of tibolone
Incubation
time
%
Tibolone
% 4-
tibolone
%
3-OH-
tibolone
%
3-OH-
tibolone
PRAB-36 cells
Input: 3H(tibolone) 0 d 80 20
3 d 81 19
6 d 100
Input:
3H(4-tibolone) 0 d 100
3 d 100
6 d 100
Input:
3H(3-OH-tibolone) 0 d 100
3 d 100
6 d 100
Input:
3H(3-OH-tibolone) 0 d 100
3 d 100
6 d 100
PRAB-36 cells were cultured for 0, 3, or 6 d in medium containing
5% DCC-FBS, in the presence of 50 nM 3H(tibolone), 3H(4-tibolone),
3H(3-OH-tibolone), or 3H(3-OH-tibolone). HPLC analysis was per-
formed to measure conversion of the input compound into its possible
metabolic products.
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at 4 C. The proteins were separated on a sodium dodecyl sulfate-
polyacrylamide gel and transferred to nitrocellulose (Schleicher &
Schuell, Inc., Keene, NH). The PRA/B (C-20) rabbit polyclonal anti-
body (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) was incubated
with the membrane as follows. The membrane was rinsed with PBS-
Tween (0.5%) and blocked for 1 h with blocking solution. The PRA/B
antibody was diluted 1:2000 in blocking solution and incubated with
the membrane for 1 h. The membrane was washed four times for 15
min each time with PBS-Tween. Antibody-peroxidase conjugate was
diluted in blocking solution and incubated with the membrane for 1 h.
The membrane was washed four times for 15 min each time with
PBS-Tween. The PRA and PRB bands were detected using the Lu-
minol chemiluminescence procedure (NEN Life Science Products,
Boston, MA) and was visualized by exposing the blot to x-ray film
(Kodak X-Omat, Eastman Kodak Co., New Haven, CT) for at least
1 min.
Northern blotting
For total RNA isolation, cells were cultured in DMEM/Ham’s F-12
and 5% DCC-FBS for the indicated time in the presence or absence of
1 nm MPA, 100 nm tibolone, or 100 nm 4-tibolone. Total RNA was
isolated by lysing the cells with 3 m lithium chloride/6 m urea (18);
subsequently, the RNA was purified and separated as described by
Blok et al. (19). As a probe for fibronectin, a 361-bp fragment of
fibronectin cDNA was used. As a probe to detect IGF-binding pro-
tein-3 (IGFBP-3) mRNA on the Northern blot, a 2.4-kb EcoRI cDNA
fragment containing the complete mouse IGFBP-3-coding sequence
was used. This cDNA was provided by Dr. S. L. S. Drop (Erasmus
Medical Center, Rotterdam, The Netherlands).
Statistics
Statistical analysis was performed using SPSS software version 10.05,
patched with version 10.07 (SPSS, Inc., Chicago, IL). The experiments
described in Figs. 2 and 3 were repeated three times, and paired-sample
t tests were performed. Differences between control and treatments were
considered significant at P values less than 0.01.
Results
Tibolone and its metabolites
Depending on the tissue or cell line to which tibolone is
administered, the compound can be metabolized differently.
There are three derivatives to which tibolone can be con-
verted: 3-OH-tibolone (Org-4094), 3-OH-tibolone (Org-
30126), and4-tibolone (Org-OM38). These compounds were
used with tibolone and MPA in our studies. MPA was chosen
as the progestagen because this compound is used in clinical
practice.
To determine to what extent tibolone is converted to
the two estrogenic metabolites (3-OH-tibolone and 3-
OH-tibolone) or the progestagenic/androgenic metabolite
(4-tibolone) in the progesterone receptor-expressing
PRAB-36 cell line, HPLC measurements were performed.
PRAB-36 cells were cultured in the presence of [3H]tibo-
lone, [3H]3-OH-tibolone, [3H]3-OH-tibolone, or [3H]4-
tibolone for 0, 3, or 6 d. Subsequent conversion to tibolone
FIG. 2. Progesterone receptor-expressing Ishikawa cells are growth-inhibited by tibolone. Parental Ishikawa cells (A) and PRAB-36 cells (B)
were cultured in DMEM/Ham’s F-12 supplemented with DCC-FBS for 10 d in the absence of hormone (Con) or in the presence of tibolone (Tibol;
0.1 M), 4-tibolone (delta-4; 0.1 M), 3-OH-tibolone (3-OH; 0.1 M), 3-OH-tibolone (3-OH; 0.1 M), or MPA (1 nM). Cells were harvested
in 1 N NaOH and OD260 nm measurements were performed to measure cell growth. Cell growth is expressed as a percentage of control growth
(Growth %). The experiments were performed three times, and paired-sample t tests were performed. Differences between control and
treatments were considered significant (**) at P 0.01. Each bar represents the average of three different experiments SD. On the right side,
phase contrast images of cultured cells are shown.
Blok et al. • Tibolone and Endometrium J Clin Endocrinol Metab, May 2003, 88(5):2327–2334 2329
 on November 13, 2006 jcem.endojournals.orgDownloaded from 
metabolites was measured by HPLC analysis (Table 1). It
was observed that handling (evaporating the dissolvent
and dissolving the resulting powder in culture medium)
of tibolone in itself caused some conversion to 4-tibolone.
It was also observed that after 6 d of culture, all tibolone
was converted to the 4 isomer, explaining the clear pro-
gestagenic activity of tibolone in culture. At 3 d, however,
about 20% of the original amount of tibolone is metabo-
lized into one of the estrogenic metabolites, 3-OH-tibo-
lone. Despite the fact that 3-OH-tibolone, when admin-
istered alone, seems very stable in culture, 3-OH-tibolone,
which was produced from tibolone, could no longer be de-
tected in culture after 6 d. The HPLC analysis allows for
detection of sulfated forms of tibolone and its metabolites.
However, no sulfated forms of 3-OH-tibolone and 3-OH-
tibolone were detected. Our explanation is that sulfotrans-
ferase activity needs to be induced or that 3-OH-tibolone
and 3-OH-tibolone have a lower affinity to sulfotransferase
than estrone.
PRAB-36 cells cultured in the presence of tibolone are
inhibited in growth
To measure the progestagenic effects of tibolone, pa-
rental Ishikawa cells, or Ishikawa cells that had been stably
transfected with PRA and PRB (PRAB-36; Fig. 1) were
cultured in the presence or absence of tibolone or its me-
tabolites in 0.1-m concentrations. As a control for growth
inhibition, cells were also cultured in the presence of MPA
(1 nm).
Despite the fact that many reports claim the opposite
(16, 20, 21), in the parental Ishikawa cell line, using West-
ern blotting (Fig. 1), Northern blotting, and an [3H]ligand
binding assay (17), we could not detect progesterone re-
ceptor expression (Fig. 1) or androgen or estrogen receptor
expression (not shown). Furthermore, no growth regula-
tion by MPA, tibolone, or its derivatives was observed
(Fig. 2A). Only in the very early passages of the parental
Ishikawa cells were we sometimes able to show proges-
terone regulation of growth, which makes it possible that
during culture in our laboratory the parental Ishikawa
cells lost their steroid receptors. Using these unexpected
findings, however, an Ishikawa cell line expressing high
levels of PRA and PRB (PRAB-36) could be created next to
an Ishikawa cell line lacking progesterone receptor ex-
pression (IK-par) (17).
When PRAB-36 cells were cultured in the presence of
tibolone or 4-tibolone, a significant inhibition of growth
could be measured (Fig. 2B). The extent of the inhibition was
comparable, with maximal growth inhibition observed dur-
ing culture in the presence of MPA. Culture in the presence
of 3-OH-tibolone also resulted in a small, but significant,
inhibition of cell growth in the PRAB-36 cell line. This inhi-
bition was markedly less than that observed when the PR-
containing cells were cultured in the presence of MPA (Fig.
2B). Using another Ishikawa subline that expressed only PRB
receptors (PRB-59), very similar results were obtained (data
not shown).
To measure the ED50 of tibolone and
4-tibolone compared
with that of MPA, dose-response experiments were per-
formed. The ED50 values for both tibolone and 
4-tibolone
were approximately 1 nm, while the ED50 for MPA was less
than 0.1 nm (Fig. 3). These data are comparable to observa-
tions in other reports (3).
A time-course experiment was performed to determine
when growth inhibition became first visible. Cells were cul-
tured in the presence of tibolone, 3-OH-tibolone, 3-OH-
tibolone 4-tibolone, or MPA for 3, 6, 10, and 14 d. After 6 d
of culture in the presence of tibolone, 4-tibolone, and MPA,
FIG. 3. Dose-response curve for PRAB-36 cells cultured in the pres-
ence of tibolone, 4-tibolone, or MPA. Cells were cultured in the
presence of different concentrations of tibolone (top panel), 4-
tibolone (middle panel), or MPA (bottom panel) for 10 d. Cells were
harvested in 1 N NaOH, and OD260 nm measurements were per-
formed to measure cell growth. Cell growth is expressed as a
percentage of control growth (Growth %). The experiments were
performed three times, and paired-sample t tests were performed.
Differences between control and treatments were considered sig-
nificant (**) at P  0.01. Each bar represents the average of three
different experiments  SD.
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a clear growth inhibition was observed (Fig. 4). Furthermore,
during growth inhibition, cell growth did not come to a
complete standstill; rather, the growth rate became severely
inhibited (Fig. 4).
Tibolone acts as a progestagenic compound on PRAB-36
endometrial cancer cell lines
Incubation of a progesterone-responsive endometrial can-
cer cell line in the presence of tibolone, 4-tibolone, or 3-
OH-tibolone results in significant growth inhibition (Fig. 2B).
Because progesterone receptor-negative parental Ishikawa
cells do not show this growth inhibition (Fig. 2A), it is likely
that the progesterone receptor is involved. To investigate this
more thoroughly, we made use of the pure antiprogestagen
Org-31489 to inhibit the progestagenic effects of tibolone,
4-tibolone, and MPA on cell growth. Tibolone-, 4-tibo-
lone-, and MPA-induced growth inhibition could readily be
reversed by administration of the pure antiprogestagen Org-
31489 (Fig. 5).
FIG. 4. Time course of growth inhibition by MPA, tibolone, and its
derivatives. PRAB-36 cells were cultured for different periods (3, 6,
10, and 14 d) in the absence (Con) or presence of tibolone (Tibol; 0.1
M), 4-tibolone (delta-4; 0.1 M), 3-OH-tibolone (3-OH; 0.1 M),
3-OH-tibolone (3-OH; 0.1 M), or MPA (1 nM). Cells were harvested
in 1 N NaOH, and OD260 nm measurements were performed to mea-
sure cell growth. Growth is expressed as micrograms of DNA per well.
Each figure represents a single experiment, and each point in the
curve represents the mean  SD of four wells.
FIG. 5. Inhibition of progestagenic effects of tibolone and its de-
rivatives by the antiprogestagin Org-31489. PRAB36 cells were
cultured for 10 d under control conditions (Con) or in the presence
of the antiprogestagin Org-31489 (10 nM Anti or 100 nM Anti),
tibolone (top panel; 1 nM Tibol, 10 nM Tibol), 4-tibolone (middle
panel; 1 nM delta-4, 10 nM delta-4), MPA (bottom panel; 0,1 nM
MPA, 1 nM MPA), or a combination of hormones and antihormones
as indicated. Cells were harvested in 1 N NaOH and OD260 nm
measurements were performed to measure cell growth. Growth is
expressed as micrograms of DNA per well. The figure represents
a single representative experiment, and each point in the curve
represents the mean  SD of four wells.
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Using microarray technology, several progesterone-regu-
lated genes were identified (Ref. 17; see Footnote 1).2 Two of
those genes (fibronectin and IGFBP-3) were rapidly regu-
lated by progesterone (8–72 h) and were used in the current
studies to investigate the progestagenic properties of tibo-
lone. It was observed that regulations of these genes by
tibolone, 4-tibolone, and MPA were similar (Fig. 6), indi-
cating that tibolone and 4-tibolone also have a progesta-
genic effect on gene regulation in the endometrial cancer cell
lines used in this study.
Discussion
The presence of estrogens and the absence of progestagens
results in growth of the endometrium, which may lead to
endometrial hyperplasia. When this hormonal regime is
maintained, hyperplasia will progress into endometrial ad-
enocarcinoma in about 25% of the cases (22). Because of this,
unopposed estrogens are usually not administered to relieve
climacteric problems or to prevent osteoporosis in women
who still have a uterus, but the hormone is always provided
in combination with progesterone. Progesterone opposes the
activity of estrogens in several ways: progesterone decreases
the expression of estrogen receptors in the endometrium (23);
progesterone increases the conversion of estradiol into the
less potent estrone in the glandular epithelium (24, 25); and
progesterone induces enzyme activity (sulfotransferase),
which can result in inactivation of estrogens (10). Further-
more, it is likely that some genes that are regulated by pro-
gesterone oppose the growth-stimulating activities of estro-
gen-regulated genes.
Tibolone is used for the treatment of climacteric com-
plaints and the prevention of osteoporosis (26). Tibolone
exerts tissue-specific effects (4), showing in some tissues a
more potent estrogenic activity; in other tissues, such as
endometrium, the progestagenic properties of tibolone seem
more pronounced (27). The effects and putative adverse ef-
fects of tibolone treatment on the endometrium have recently
been discussed (27–30).
The current investigations were performed to dissect out
the progestagenic effects of tibolone on the endometrium.
Therefore, a human endometrial cancer cell line was used
that expressed high levels of PRA and PRB, did not express
estrogen or androgen receptors, and consequently did not
respond to estrogen or androgen treatment (17). Using this
cell line, a profound growth inhibitory effect of tibolone,
4-tibolone, and MPA was observed. Surprisingly, when
progesterone-responsive cells were cultured in the presence
of the estrogenic 3-OH metabolite of tibolone, cell growth
was also slightly inhibited. This effect of 3-OH-tibolone was
unexpected, because HPLC analyses failed to show any con-
version of 3-OH-tibolone into the progestagenic/andro-
genic metabolite 4-tibolone. Differences in experimental
conditions between the growth experiments and the HPLC
experiments, or the sensitivity of the HPLC measurements
may be at the basis of this. However, the observation that
3-OH-tibolone exhibits weak progestagenic activities has
also been made by others. Using human endometrium tissue
cultures, Markiewicz and Gurpide (3) showed the regulation
of expression of several progesterone-regulated proteins by
tibolone, 4-tibolone, and 3-OH-tibolone. These results in-
dicate that 3-OH-tibolone, most likely through conversion
to the 4 metabolite of tibolone, may act as a weak pro-
gestagen.
The administration of tibolone itself resulted in a signifi-
cant reduction of cell growth. Because the affinity of tibolone
for progesterone receptors is very low, local conversion into
its progestagenic4 isomer was expected. To investigate this,
progesterone-expressing PRAB-36 cells were cultured for 0,
2 Hanekamp, E. E., S. C. J. P. Gielen, E. Smid-Koopman, E. C. M.
Ku¨hne, P. E. De Ruiter, S. Chadha-Ajwani, A. O. Brinkmann, J. A.
Grootegoed, C. W. Burger, F. J. Huikeshoven, and L. J. Blok, submitted
for publication.
FIG. 6. Regulation of expression of fibronectin and
IGFBP-3 by tibolone and its derivatives. PRAB-36 cells
were cultured in the absence (Con) or presence of MPA (1
nM), tibolone (0.1 M), or 4-tibolone (0.1 M). RNA was
isolated, electrophoresed, and blotted. The Northern blots
were hybridized with probes for fibronectin or IGFBP-3.
The image of the ethidium bromide-stained gel was used to
verify equal loading of total RNA samples on the gel.
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3, or 6 d in the presence of 50 nm [3H]tibolone. It was ob-
served that after 3 d of incubation in the presence of 50 nm
[3H]tibolone, the compound had been converted to [3H]3-
OH-tibolone (19%) and [3H]4-tibolone (81%). Despite the
fact that [3H]3-OH-tibolone, when administered alone,
seems very stable in culture, [3H]3-OH-tibolone, which was
produced from tibolone, could no longer be detected in cul-
ture after 6 d. This observation seems to indicate that ad-
ministration of tibolone and conversion into its 4 isomer
have a stimulatory effect on the activity of the enzymes
involved in the conversion of 3-OH-tibolone into 4-tibo-
lone (3HSD). In agreement with this, Tang et al. (31) showed
that progestagens are indeed capable of inducing 3HSD
activity in the endometrium. Another interesting finding was
that although sulfotransferase activity is documented for
Ishikawa cells (32, 33), no sulfation of tibolone or its meta-
bolic products was observed. Sulfation of tibolone, 3-OH-
tibolone, and 3-OH-tibolone has been reported; however, it
is possible that the specific enzymes responsible for sulfation
of these compounds are not active in Ishikawa cells.
The experiments performed to date have indicated that
tibolone acted mainly through its 4 metabolite to induce
growth inhibition of progesterone receptor-responsive en-
dometrial cancer cells through activation of the hormone
receptor. Using the antiprogestagin Org-31489 in combina-
tion with tibolone, 4-tibolone, or MPA indeed showed a
reversion of the progestagenic effects. Furthermore, it was
observed that 10 nm of the antiprogestagen was effective in
reverting the effects of 1 nm MPA and 10 nm tibolone or
4-tibolone. This indicated that the affinity of MPA for the
progesterone receptor is approximately 10-fold higher then
the affinity of tibolone or 4-tibolone for the receptor. These
results fit very well with the finding that the ED50 for growth
inhibitory effects on PRAB-36 cells for MPA is 10-fold lower
than the ED50 for tibolone and its 
4 isomer.
Because tibolone, 4-tibolone, and MPA had comparable
growth-inhibiting effects on the progesterone receptor-
expressing endometrial cancer cell line PRAB-36, and be-
cause these effects could only be measured after several days
of culture, it was decided to also study earlier and more direct
effects of progestagens on PRAB-36 cells. Regulation of
mRNA expression of IGFBP-3 and fibronectin was chosen for
further evaluation, because IGFBP-3 and fibronectin had
both been reported as early (effects were observed at 8 h)
progesterone-regulated genes (Ref. 17; see Footnotes 1 and 2).
In the current investigations it was shown that incubation of
PRAB-36 cells in the presence of tibolone, 4-tibolone, and
MPA resulted in a reproducible decline in the expression of
fibronectin and IGFBP-3 mRNA. According to Dai et al. (34),
inhibition of expression of the cellular adhesion molecule
fibronectin could play a role in inhibiting endometrial cancer
cell invasiveness.
In summary, using a progesterone-responsive endome-
trial cancer cell line it was shown that the 4 metabolite of
tibolone displayed clear progestagenic effects on cell growth
and gene regulation. Furthermore, it was shown that 3-
OH-tibolone had some minor, but significant, inhibitory ef-
fects on cell growth. These results are in good accordance
with data from the literature and indicate that tibolone, the
4 metabolite of tibolone, and, to some extent, 3-OH-
tibolone exert clear progestagenic effects on a progesterone-
sensitive endometrial cancer cell line. Tibolone and most
likely 3-OH-tibolone are converted into the progestagenic
4 metabolite.
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